Asianet Newsable on MSN
Hims & Hers hit a GLP-1 speed bump this year — but growth is just cooling, not cracking
Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster ...
If you have been wondering whether Hims & Hers Health is still a smart buy after its huge run, you are not alone. This stock has quickly moved from niche telehealth play to mainstream market talking ...
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is a trending stock: Facts to know before betting on it
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo Nordisk’s ...
The trajectory of well-known health and wellness platform Hims & Hers is one that most entrepreneurs and investors would hope for. Not even six years old, the company has for the most part experienced ...
By taking into account a patient’s unique biology, psychology, environment and behaviors, Hims & Hers is able to offer access ...
The telehealth company is being criticized for its Super Bowl weight loss commercial. (Hims & Hers via YouTube) During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.
Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its telehealth ...
Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make its weight loss drug Wegovy available on the telehealth company's platform ...
Online health and wellness company Hims & Hers bumped its full-year revenue forecast higher following strong growth in subscribers and double-digit net income in the first quarter. The company, which ...
Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims & Hers' ...
The moment Hims & Hers reports we’ll have live updates with news and analysis updating below. You don’t have to do anything, just leave this page open and new updates will appear directly below. Here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results